Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


High-Ranking Meddling Behind Sarepta Duchenne Drug Delay?

Executive Summary

Involvements of senior FDA officials may be the reason the agency put off its much-anticipated decision last week on Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy drug eteplirsen, analysts said.


Related Content

Sarepta Smacked By FDA's Curiously Timed Compassionate Use Revisions
BioMarin Kills Kyndrisa, But Duchenne Pursuit Not Over
Limbo Land For Sarepta, Duchenne And Rare Diseases
Data Trumps Anecdotes, Emotion At Sarepta Panel
US Capitol Capsule: NIH chief 'cranks it up' with captains of industry


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts